Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives $51.00 Average Price Target from Analysts

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWRGet Free Report) have been assigned an average rating of “Moderate Buy” from the nine ratings firms that are covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $50.00.

ARWR has been the subject of several research reports. Citigroup increased their target price on Arrowhead Pharmaceuticals from $33.00 to $34.00 and gave the company a “neutral” rating in a research report on Wednesday, February 7th. Chardan Capital reiterated a “buy” rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday. Morgan Stanley decreased their price target on Arrowhead Pharmaceuticals from $36.00 to $27.00 and set an “equal weight” rating for the company in a research note on Monday, May 13th. Royal Bank of Canada reissued an “outperform” rating and issued a $50.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, February 7th. Finally, HC Wainwright reissued a “buy” rating and issued a $90.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Monday.

View Our Latest Analysis on Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals Stock Up 2.7 %

Shares of ARWR stock opened at $25.29 on Friday. Arrowhead Pharmaceuticals has a twelve month low of $20.67 and a twelve month high of $39.83. The company has a market cap of $3.14 billion, a P/E ratio of -5.95 and a beta of 0.94. The business has a fifty day simple moving average of $24.56 and a 200 day simple moving average of $28.49.

Arrowhead Pharmaceuticals (NASDAQ:ARWRGet Free Report) last posted its earnings results on Thursday, May 9th. The biotechnology company reported ($1.02) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.96). Arrowhead Pharmaceuticals had a negative net margin of 163.32% and a negative return on equity of 140.72%. Arrowhead Pharmaceuticals’s revenue for the quarter was down 100.0% on a year-over-year basis. During the same period in the prior year, the company earned $0.45 earnings per share. As a group, equities research analysts anticipate that Arrowhead Pharmaceuticals will post -3.05 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Victoria Vakiener sold 1,799 shares of the firm’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $23.31, for a total transaction of $41,934.69. Following the completion of the sale, the director now owns 30,205 shares of the company’s stock, valued at $704,078.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Arrowhead Pharmaceuticals news, Director Victoria Vakiener sold 1,799 shares of the firm’s stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $23.31, for a total value of $41,934.69. Following the completion of the sale, the director now owns 30,205 shares of the company’s stock, valued at $704,078.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Hongbo Lu acquired 1,000 shares of Arrowhead Pharmaceuticals stock in a transaction on Monday, March 18th. The stock was purchased at an average cost of $27.49 per share, with a total value of $27,490.00. Following the purchase, the director now directly owns 31,680 shares of the company’s stock, valued at approximately $870,883.20. The disclosure for this purchase can be found here. 4.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Arrowhead Pharmaceuticals

A number of hedge funds have recently added to or reduced their stakes in ARWR. Raymond James & Associates grew its stake in Arrowhead Pharmaceuticals by 47.8% in the third quarter. Raymond James & Associates now owns 28,343 shares of the biotechnology company’s stock valued at $762,000 after acquiring an additional 9,167 shares during the period. Victory Capital Management Inc. lifted its holdings in shares of Arrowhead Pharmaceuticals by 8.6% in the third quarter. Victory Capital Management Inc. now owns 48,948 shares of the biotechnology company’s stock valued at $1,315,000 after purchasing an additional 3,890 shares in the last quarter. Fox Run Management L.L.C. boosted its position in shares of Arrowhead Pharmaceuticals by 34.0% during the third quarter. Fox Run Management L.L.C. now owns 11,780 shares of the biotechnology company’s stock valued at $317,000 after buying an additional 2,988 shares during the last quarter. New York State Common Retirement Fund boosted its position in shares of Arrowhead Pharmaceuticals by 2.4% during the third quarter. New York State Common Retirement Fund now owns 42,866 shares of the biotechnology company’s stock valued at $1,152,000 after buying an additional 999 shares during the last quarter. Finally, Moody Aldrich Partners LLC boosted its position in shares of Arrowhead Pharmaceuticals by 3.7% during the third quarter. Moody Aldrich Partners LLC now owns 59,669 shares of the biotechnology company’s stock valued at $1,603,000 after buying an additional 2,134 shares during the last quarter. Institutional investors and hedge funds own 62.61% of the company’s stock.

About Arrowhead Pharmaceuticals

(Get Free Report

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.

Recommended Stories

Analyst Recommendations for Arrowhead Pharmaceuticals (NASDAQ:ARWR)

Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.